Daehan New Pharm Co. Ltd (054670) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Daehan New Pharm Co. Ltd (054670) has a cash flow conversion efficiency ratio of 0.034x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩4.43 Billion ≈ $3.00 Million USD) by net assets (₩129.44 Billion ≈ $87.72 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Daehan New Pharm Co. Ltd (054670) defensive interval to measure how many days the company can operate on defensive assets alone.
Daehan New Pharm Co. Ltd - Cash Flow Conversion Efficiency Trend (2014–2024)
This chart illustrates how Daehan New Pharm Co. Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Daehan New Pharm Co. Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Daehan New Pharm Co. Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
YES24 Co.Ltd
KQ:053280
|
0.014x |
|
Kamat Hotels (I) Limited
NSE:KAMATHOTEL
|
0.085x |
|
Regal Holding Co Ltd
TW:4807
|
-0.239x |
|
Dae Young Pkg
KO:014160
|
-0.015x |
|
Inv Tricahue
SN:TRICAHUE
|
0.051x |
|
ESTsoft Corp
KQ:047560
|
-0.074x |
|
RTG Mining Inc
TO:RTG
|
0.000x |
|
Shagrir Group Vehicle Services Ltd
TA:SHGR
|
0.072x |
Annual Cash Flow Conversion Efficiency for Daehan New Pharm Co. Ltd (2014–2024)
The table below shows the annual cash flow conversion efficiency of Daehan New Pharm Co. Ltd from 2014 to 2024. For the full company profile with market capitalisation and key ratios, see Daehan New Pharm Co. Ltd (054670) total market value.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩125.44 Billion ≈ $85.01 Million |
₩18.95 Billion ≈ $12.84 Million |
0.151x | +31.44% |
| 2023-12-31 | ₩109.36 Billion ≈ $74.11 Million |
₩12.57 Billion ≈ $8.52 Million |
0.115x | -16.99% |
| 2022-12-31 | ₩102.96 Billion ≈ $69.77 Million |
₩14.25 Billion ≈ $9.66 Million |
0.138x | -31.16% |
| 2021-12-31 | ₩82.47 Billion ≈ $55.89 Million |
₩16.58 Billion ≈ $11.24 Million |
0.201x | -15.19% |
| 2020-12-31 | ₩57.13 Billion ≈ $38.72 Million |
₩13.55 Billion ≈ $9.18 Million |
0.237x | -36.75% |
| 2019-12-31 | ₩61.07 Billion ≈ $41.38 Million |
₩22.89 Billion ≈ $15.51 Million |
0.375x | -21.12% |
| 2018-12-31 | ₩43.08 Billion ≈ $29.19 Million |
₩20.47 Billion ≈ $13.87 Million |
0.475x | +1113.94% |
| 2017-12-31 | ₩51.72 Billion ≈ $35.05 Million |
₩-2.42 Billion ≈ $-1.64 Million |
-0.047x | -138.14% |
| 2016-12-31 | ₩71.20 Billion ≈ $48.25 Million |
₩8.75 Billion ≈ $5.93 Million |
0.123x | +21.58% |
| 2015-12-31 | ₩77.20 Billion ≈ $52.32 Million |
₩7.80 Billion ≈ $5.29 Million |
0.101x | -25.43% |
| 2014-12-31 | ₩73.89 Billion ≈ $50.07 Million |
₩10.02 Billion ≈ $6.79 Million |
0.136x | -- |
About Daehan New Pharm Co. Ltd
Daehan Nupharm Co.,Ltd. manufactures and sells pharmaceuticals and veterinary products in South Korea and internationally. It offers pharmaceuticals drugs for cardiovascular, endocrine system, neuropsychiatric, gastrointestinal, respiratory system, antipyretic, analgesic, anti-inflammatory, anti-infective, musculoskeletal, osteoporosis, anti-cancer, urogenital system, antifungal, antiviral, hormo… Read more